1. business and industrial
2. company
3. earnings

Regional Daily, 17 October 2014
5
Regional Daily
Ideas Troika
Top Stories
Hong Kong Real Estate
NEUTRAL
Pg2
In September, property sales of our 20 selected developers recorded a 27%
MoM and 10% YoY increase, thanks to more presales launches. Going
forward, we do not see big changes in selling prices and expect the inventory
level to keep rising.
Analyst: John So (john.so@rhbgroup.com)
Top Glove (TOPG MK)
Consumer Non-cyclical - Rubber Products
BUY MYR4.54 TP: MYR5.06
Mkt Cap : USD858m
Pg3
We upgrade Top Glove to BUY from Neutral, with an unchanged TP of
MYR5.06 (11.5% upside, 17x FY15F P/E). At yesterday’s briefing,
management gave clearer guidance on future growth plans, which include
focusing on production efficiency.
Analyst: Jerry Lee (jerry.lee@rhbgroup.com)
M1 (M1 SP)
Communications - Telecommunications
BUY SGD3.44 TP: SGD4.40
Mkt Cap : USD2,511m
Pg4
M1’s results met expectations. The strong prepaid data growth and more
postpaid subs exceeding their data allowances propped up double-digit YoY
growth in 3Q14 EBITDA and core earnings. Maintain BUY, as we raise our
DCF-based TP to SGD4.40 after rolling forward our valuation to FY16.
Analyst: Jeffrey Tan (jeffrey.tan@rhbgroup.com)
Keppel REIT (KREIT SP)
Property - REITS
BUY SGD1.18 TP: SGD1.18
Mkt Cap : USD2,765m
Pg5
All eyes are now on OFC to hit its breakeven rent, when its income support
ends in 2016-2017. We assume coverage of Keppel REIT with a HOLD and
DDM-based TP of SGD1.18 (CoE: 7.0%, TG: 1%), implying 0% upside.
Analyst: Ivan Looi (ivan.looi@sg.oskgroup.com)
Other Key Stories
Malaysia
BAT (ROTH MK)
Consumer Non-cyclical – Tobacco
SELL MYR66.70 TP: MYR57.80
KPJ Healthcare (KPJ MK)
Consumer Non-cyclical - Healthcare
NEUTRAL MYR3.71 TP: MYR3.67
See important disclosures at the end of this report
Pg6
Better Than Expected
Analyst: Fong Kah Yan (fong.kah.yan@rhbgroup.com)
Pg7
Taking Steps To Address Growing Demand
Analyst: Alexander Chia (alexander.chia@rhbgroup.com)
Powered by EFATM Platform
1
Sector News Flash, 16 October 2014
Real Estate
NEUTRAL (Maintained)
Macro
Risks
Home Sales Likely To Recover In October
Growth
Value






3

2

2
2
China’s property stocks index
What's new?
Index
260
In September, property sales of our 20 selected developers recorded a
27% MoM and 10% YoY increase, thanks to more presales launches.
Going forward, we do not see big changes in selling prices and expect
the inventory level to keep rising.
240
220
200
180
160
140
Our view:
120
100

80
Source: RHB, Bloomberg
Contracted sales growth
Ticker
3383 HK
688 HK
884 HK
81 HK
2007 HK
3333 HK
3900 HK
1813 HK
960 HK
813 HK
1918 HK
Company
Agile Property
China Overseas
CIFI Holdings
COGO
Country Garden
Evergrande Real Estate
Greentown China
KWG Property
Longfor
Shimao Property
Sunac China
Aggregate growth rate
FY13
YoY (%)
22%
18%
61%
26%
123%
9%
22%
33%
20%
46%
23%
FY14F
YoY (%)
4%
5%
35%
10%
10%
20%
-4%
26%
6%
9%
17%
28%
10%
Source: Bloomberg



Developers’ September contracted sales up 10% YoY. The easing of
home tightening measures continues to lead to a recovery in home sales
volume. Developers have stated that home sales looked satisfactory in
the first 10 days of October, thanks to changes in the People's Bank of
China’s (PBOC) second home mortgage policies.
A stronger rebound likely in major cities. Given the relaxation of
second home mortgage, we believe demand from home upgraders for
second homes will likely be stronger in major cities than in small Tier-3
cities. We expect home sales to recover faster in major cities like Beijing,
Guangzhou and Nanjing, and this would directly benefit KWG Property
(1813 HK, BUY, TP: HKD7.60) and Shimao Property (813 HK, BUY, TP:
HKD20.30).
Potential price downtrend amid rising supply. We expect the
inventory level to increase following massive new launches by
developers. We estimate about a 5% home price correction in the next 12 quarters, which could drag listed developers’ GPM down c.1-2ppts in
2015.
Awaiting positive signals from liquidity. The recent policy changes are
positive for the property sector but have yet to trigger a re-rating. We
believe the liquidity is still tight and would be the bottleneck for the home
sales volume rebound. We shall await more positive changes in M2,
aggregate social financing and thus, total mortgage loan growth. The
sector is now trading at a 49% discount to the net asset value (NAV),
similar to the 5-year mean at 45%, which we regard as not attractive
enough. However, the sales volume rebound in October may provide
short-term trading opportunities for large developers, including China
Overseas Land & Investment Ltd (688 HK, TAKE PROFIT, TP:
HKD22.60) and Shimao Property.
Ticker
Rating
TP (HKD)
Agile Property
3383 HK
BUY
4.8
4.09
17%
13.80
70%
China Overseas
688 HK
TAKE PROFIT
22.6
21.05
7%
25.20
16%
CIFI Holdings
884 HK
BUY
2.1
1.45
45%
3.90
63%
COGO
81 HK
NEUTRAL
6.2
4.28
45%
9.50
55%
John So +852 2103 5888
Country Garden
2007 HK
NEUTRAL
3.7
2.91
29%
5.50
47%
john.so@rhbgroup.com
Evergrande
3333 HK
SELL
2.8
2.98
-6%
5.70
48%
Greentown China
3900 HK
NEUTRAL
7.3
7.66
-5%
18.20
58%
KWG Property
1813 HK
BUY
7.6
5.36
42%
15.20
65%
Longfor
960 HK
NEUTRAL
10.2
9.09
12%
14.60
38%
Shimao Property
813 HK
BUY
20.3
15.92
28%
29.00
45%
Sunac
1918 HK
BUY
7.6
6.45
18%
15.30
Powered by
EFATM Platform
58%2
Company
See important disclosures at the end of this report
Source: Company data, RHB
Upside
ENAV
(HKD)
Current
ENAV
discount
Price
(HKD)
Company Update, 17 October 2014
Top Glove (TOPG MK)
Buy (from Neutral)
Consumer Non-cyclical - Rubber Products
Market Cap: USD858m
Target Price:
Price:
MYR5.06
MYR4.54
Macro
Risks
Trade With Caution
Growth
Value
Top Glove (TOPG MK)
Price Close
Relative to FTSE Bursa Malaysia KLCI Index (RHS)
6.30
109
6.10
105
5.90
101
5.70
97
5.50
93
5.30
89
5.10
85
4.90
81
4.70
77
4.50
73
4.30
25
69
0
0
.
2
0
0
We upgrade Top Glove to BUY from Neutral, with an unchanged TP of .
0
MYR5.06 (11.5% upside, 17x FY15F P/E). The recent sell-down has led to 0
the stock being traded at a more attractive valuation. At yesterday’s 0
briefing, management gave clearer guidance on future growth plans,
which include focusing on production efficiency. Still, we advise
investors to be cautious due to the volatility in the equity market.

20
15

Aug-14
Jun-14
Apr-14
Feb-14
Dec-13
5
Oct-13
Vol m
10
Source: Bloomberg
Avg Turnover (MYR/USD)
Cons. Upside (%)
Upside (%)
52-wk Price low/high (MYR)
Free float (%)
Share outstanding (m)
Shareholders (%)
Tan Sri Dato Sri Lim Wee Chai
KWAP
EPF
2.57m/0.80m
7.9
11.5
4.50 - 6.03
47
621
28.9
9.0
6.4
Share Performance (%)
YTD
1m
3m
6m
12m
Absolute
(19.4)
(7.9)
(2.8)
(4.6)
(21.1)
Relative
(15.1)
(4.6)
2.5
(1.4)
(20.8)


Key takeaways. We attended Top Glove’s analyst briefing yesterday.
Key takeaways were: i) global demand growth for healthcare is expected
to be c.8% per annum, ii) its margins have compressed due to intense
competition, iii) it will continue to increase its nitrile production capacity,
and iv) the surge in demand for gloves from the Ebola outbreak may not
be substantial at this moment but management expects more orders
from countries like Spain, Denmark and the UK, where its clients supply
to global bodies like the World Health Organisation (WHO) and United
Nations Educational, Scientific and Cultural Organisation (UNESCO).
Capacity expansion. Management guided that its 2015 production
capacity will rise to 2.0bn pieces per annum before increasing to 4.4bn
pieces per annum in 2016. By Sep 2016, it expects total installed
capacity to hit 49bn pieces per annum (42.6bn pieces currently). Top
Glove has allocated capex of MYR200m each for FY15 and FY16
respectively, and has set aside MYR150m for possible acquisitions. The
expansion plan will focus on boosting its nitrile glove capacity in tandem
with growing demand. It will also continue to better production efficiency
to mitigate the margin erosion that comes from intense competition and
escalating operating expenses (electricity, fuel prices etc).
Efficiency is the key. Going forward, we think that competition within
the industry may remain intense and glove makers would need to
continue to focus on improving production efficiency to mitigate the
downward pressure on their earnings margins.
Raise to BUY. We upgrade Top Glove to BUY (vs Neutral) with
unchanged MYR5.06 TP pegged to a 17x FY15F P/E, the mean of its
historical trading band. The recent selldown has led to it being traded at
more attractive valuations. Top Glove has solid fundamentals, ie a robust
balance sheet (net cash), healthy cash flow and decent dividend yields
of 3.3-3.5%. However, as market conditions are volatile, we advise
investors to be cautious.
Forecasts and Valuations
Aug-12
Aug-13
Aug-14
2,314
2,313
2,276
2,516
2,715
Reported net profit (MYRm)
203
197
180
185
189
Recurring net profit (MYRm)
202
186
180
185
189
Recurring net profit growth (%)
78.5
(8.0)
(3.0)
2.9
2.0
Recurring EPS (MYR)
0.33
0.30
0.29
0.30
0.30
DPS (MYR)
0.16
0.16
0.16
0.15
0.15
Recurring P/E (x)
13.9
15.2
15.6
15.2
14.9
P/B (x)
2.24
2.11
2.02
1.86
1.75
P/CF (x)
10.6
11.6
9.3
9.9
9.6
3.5
3.5
3.5
3.3
3.4
9.09
9.23
8.93
7.86
7.41
Total turnover (MYRm)
Shariah compliant
Jerry Lee 603 9207 7622
jerry.lee@rhbgroup.com
Dividend Yield (%)
EV/EBITDA (x)
Return on average equity (%)
Net debt to equity (%)
Our vs consensus EPS (adjusted) (%)
See important disclosures at the end of this report


2

.
2
0
.
2




Source: Company data, RHB
17.1
net cash
15.2
13.2
net cash
net cash
Aug-15F
12.7
net cash
(7.8)
Powered by EFATM Platform
Aug-16F
12.1
net cash
(15.3)
3
9MFY14 Results Review, 17 October 2014
M1 (M1 SP)
Buy (Maintained)
Communications - Telecommunications
Market Cap: USD2,511m
Target Price:
Price:
SGD4.40
SGD3.44
Macro
Risks
Upwardly Mobile
Growth
Value
M1 (M1 SP)
Price Close
Relative to Straits Times Index (RHS)
3.90
107
3.80
105
3.70
103
3.60
100
3.50
98
3.40
96
3.30
94
3.20
91
3.103
89
3
0
0
.
2
0
0
M1’s 9M14 results met expectations. Strong prepaid data growth .
0
coupled with more postpaid subs exceeding their data allowances 0
propped up double-digit YoY growth in 3Q14 EBITDA and core 0
earnings. While SAC may see a further rise in 4Q14, M1’s accounting
policy on the iPhone should see its EBITDA margin outperforming its
peers’. Remain BUY, raising DCF-based TP to SGD4.40 (vs SGD4.20),
suggesting 27.9% upside, after rolling forward our valuation to FY16.


2
2
Aug-14
Jun-14
Apr-14
Feb-14
Dec-13
1
Oct-13
Vol m
1

Source: Bloomberg
Avg Turnover (SGD/USD)
Cons. Upside (%)
Upside (%)
52-wk Price low/high (SGD)
Free float (%)
Share outstanding (m)
Shareholders (%)
Axiata Group
Temasek Holdings
SPH Multimedia
2.91m/2.32m
9.3
27.9
3.17 - 3.83
37
931

28.6
19.3
13.5

Share Performance (%)
In line. M1’s 9M14 results were within expectations, at 77% and 76% of
our and consensus estimates respectively. The main takeaways were: i)
the surge in handset sales sequentially from the launch of the iPhone
6/6+, ii) a rising 22% of postpaid subs exceeding their data allowances,
and iii) the seasonal upswing in capex.
Other key highlights. M1 has enjoyed strong prepaid data growth with
38% of prepaid subs now on smartphones (86% on postpaid). Together
with the aggressive top-up promotions, prepaid ARPU spiked by 14%
QoQ, offsetting the weakness in roaming revenue and the Government’s
clampdown on SIM ownership. It expects fibre broadband ARPU to rise
further (3Q14: +7% QoQ), which suggests strong demand for the
promotional 1Gbps fibre plan that is priced very competitively in the
market (see Figure 5).
SAC may pick up further in 4Q14. Following two consecutive quarters
of contraction, M1’s subscriber acquisition cost (SAC) rose 38% QoQ
(+13.2% YoY), which incorporated a half-month impact from the launch
of the iPhone 6/6+. We expect SAC to increase further in 4Q14 with the
iPhone 6/6+ taking on the recently-launched Samsung Galaxy Note 4.
Nonetheless, we expect the impact on M1’s EBITDA margin to be
cushioned by the fair value accounting adopted on the iPhone.
Forecasts. We introduce our FY16 estimates but maintain our FY13-14F
numbers. Key earnings risks are: i) stronger-than-expected competition
and ii) higher-than-expected SAC.
Maintain BUY. We roll forward our valuation to FY16, which results in
our DCF-based TP rising to SGD4.40 (WACC: 7%, TG: 1.5%) from
SGD4.20. This presents an upside potential of 27.9%.
YTD
1m
3m
6m
12m
Forecasts and Valuations
Absolute
5.2
(1.7)
(4.2)
3.0
(1.4)
Total turnover (SGDm)
Relative
4.2
0.6
(1.0)
4.7
(2.2)
Shariah compliant


2

.
1
0
.
1




Dec-12
Dec-13
Dec-14F
Dec-15F
Dec-16F
1,077
1,008
1,087
1,179
1,287
Reported net profit (SGDm)
147
160
171
192
212
Recurring net profit (SGDm)
147
160
171
192
212
(10.7)
9.3
6.5
12.7
10.1
Recurring net profit growth (%)
Recurring EPS (SGD)
0.16
0.18
0.19
0.21
0.23
Jeffrey Tan +603 9207 7633
DPS (SGD)
0.15
0.21
0.21
0.21
0.21
jeffrey.tan@rhbgroup.com
Recurring P/E (x)
21.3
19.5
18.3
16.2
14.8
P/B (x)
8.97
7.91
7.97
7.80
7.30
P/CF (x)
11.4
10.4
11.4
10.6
9.6
4.2
6.0
6.0
6.0
6.0
EV/EBITDA (x)
11.4
10.8
10.4
9.4
8.8
Return on average equity (%)
43.7
43.1
43.4
48.6
51.1
Net debt to equity (%)
74.6
49.4
61.2
56.0
41.5
(1.0)
5.9
11.1
Dividend Yield (%)
Our vs consensus EPS (adjusted) (%)
Source: Company data, RHB
See important disclosures at the end of this report
Powered by EFATM Platform
4
Results Review, 17 October 2014
Keppel REIT (KREIT SP)
Neutral (from Buy)
Property - REITS
Market Cap: USD2,765m
Target Price:
Price:
SGD1.18
SGD1.18
Macro
Risks
Expiry Of MBFC 1 And 2 Rental Support Dents DPU
Growth
Value
Keppel REIT (KREIT SP)
Relative to Straits Times Index (RHS)
100
1.25
98
1.20
96
1.15
94
1.10
92
1.05
90
1.00
180
160
140
120
100
80
60
40
20
88
0
0
.
2
0
0
Keppel REIT’s 3Q14/9M14 DPU fell 6.1/3.2% YoY on the expiry of rental .
0
support from MBFC 1 and 2 as well as higher borrowing costs. All eyes 0
are now on OFC to hit its breakeven rent, when its income support ends 0
in 2016-2017. On top of that, we have factored in the MBFC 3 acquisition
into our estimates. We assume coverage of Keppel REIT with a HOLD
and DDM-based TP of SGD1.18 (CoE: 7.0%, TG: 1%), implying 0%
upside.


Aug-14
Jun-14
Apr-14
1.30
Feb-14
102
Dec-13
1.35
Oct-13
Vol m
Price Close
Source: Bloomberg
Avg Turnover (SGD/USD)
Cons. Upside (%)
Upside (%)
52-wk Price low/high (SGD)
Free float (%)
Share outstanding (m)
Shareholders (%)
5.66m/4.51m
10.2
0.0
1.11 - 1.31
58
3,002
Keppel Land
Bank of New York Mellon
DBS Group Holdings
42.2
3.4
1.2
Share Performance (%)
YTD
1m
3m
6m
12m
Absolute
(0.9)
(4.1)
(8.6)
(1.7)
(5.6)
Relative
(1.9)
(1.8)
(5.4)
0.0
(6.4)


2

.
2
0
.
2





3Q14/9M14 results in line. Keppel REIT posted a 6.1/3.2% YoY decline
in 3Q14/9M14 DPU, meeting 23%/76% of our full-year estimate. The
decrease came on the back of the expiry of rental support from Marina
Bay Financial Centre (MBFC) 1 and 2, as well as higher borrowing costs.
Its portfolio occupancy rate dipped 10bps to 99.3% and aggregate
leverage edged down to 42.1% in 3Q14 (2Q14: 42.8%), while the all-in
financing cost remained unchanged at 2.2%. The REIT renewed the
leases for 25,000 sq ft in 3Q14, at a 32.3% positive rental reversion.
Currrently, rental for only 0.2% of its total space (c.5,500 sq ft) has not
yet been renewed. It is also in advanced negotiations with tenants for the
rental review of 6.3% (c.182,000 sq ft) of its total space for 4Q14.
Room to minimise potential income shortfall. The income support for
Ocean Financial Centre (OFC) will expire in 2017. Management
previously cited the monthly breakeven rent for OFC at SGD12.60-12.70
psf, higher than our estimated average passing rent of SGD9.20 psf for
3Q14. Given the lack of new Grade A office supply in the central
business district from now until mid-2016, we see room for Keppel REIT
to minimize its potential income shortfall.
MBFC 3 to complete in December. We impute the MBFC 3 acquisition
into our estimates, assuming that it is completed in Dec 2014. We also
assume a passing rent of SGD9.11 psf/month vis-à-vis the rental support
break-even rent of SGD10.80 psf/month. In addition, we forecast a
distribution per unit (DPU) CAGR of -3.2% over FY13-16F with the
progressive expiry of income support for OFC. We assume coverage of
Keppel REIT with a HOLD, and a DDM-derived TP of SGD1.18 (CoE:
7.0%, TG: 1%). Risks include further dips in FY15-16 DPU, following the
depletion and expiry of OFC rental support.

Forecasts and Valuations
Dec-12
Dec-13
Dec-14F
Dec-15F
Dec-16F
Total turnover (SGDm)
157
174
188
179
195
Net property income (SGDm)
282
312
226
215
235
Reported net profit (SGDm)
505
726
222
245
274
Total distributable income (SGDm)
202
214
218
248
230
DPS (SGD)
0.08
0.08
0.08
0.08
0.07
Ivan Looi +65 6232 3841
DPS growth (%)
74.2
1.4
(4.5)
3.1
(8.0)
ivan.looi@sg.oskgroup.com
Recurring P/E (x)
6.0
4.4
15.6
15.3
13.8
0.89
0.84
0.87
0.89
0.90
6.6
6.7
6.4
6.6
6.1
6.5
Shariah compliant
P/B (x)
Singapore Research +65 6232 3895
Dividend Yield (%)
research@sg.oskgroup.com
Return on average equity (%)
15.0
19.7
5.4
5.8
Return on average assets (%)
8.4
11.2
3.1
3.2
3.5
5.08
4.76
1.86
1.60
2.04
0.0
0.0
0.0
Interest coverage ratio (x)
Our vs consensus EPS (adjusted) (%)
Source: Company data, RHB
See important disclosures at the end of this report
Powered by EFATM Platform
5
Results Review, 17 October 2014
BAT (ROTH MK)
Sell (Maintained)
Consumer Non-cyclical – Tobacco
Market Cap: USD5,802m
Target Price:
Price:
MYR57.80
MYR66.70
Macro
Risks
Better Than Expected
Growth
Value
BAT (ROTH MK)
Price Close
Relative to FTSE Bursa Malaysia KLCI Index (RHS)
117
74.0
114
72.0
111
70.0
108
68.0
105
66.0
102
64.0
99
62.0
96
60.0
93
58.0
90
56.02
2
2
1
1
1
1
1
87
Vol m
76.0
0
0
.
1
0
0
British American Tobacco’s (BAT) 9M14 earnings exceeded our and .
0
consensus expectations. Despite the decline in 9M14 sales volume, net 0
profit grew 12.6% YoY on the back of a growth in revenue and its lower- 0
than-expected opex. We raise our FY14F/15F earnings by 7%/4%
respectively after updating our assumptions. Maintain SELL, with a
revised DCF-based TP of MYR57.80 (from MYR56.00, 13.4% downside).

Aug-14
Jun-14
Apr-14
Feb-14
Dec-13
Oct-13

Source: Bloomberg
Avg Turnover (MYR/USD)
Cons. Upside (%)
Upside (%)
52-wk Price low/high (MYR)
Free float (%)
Share outstanding (m)
Shareholders (%)
British American Tobacco
Malaysia Ltd
EPF
11.4m/3.57m
-3.4
-13.4
58.1 - 73.4
33
286
65.0
7.8


1

.
2
0
.
1






Above expectations. British American Tobacco’s (BAT) 9M14 earnings
of MYR714.6m exceeded expectations, making up 83.6%/79% of
our/consensus full-year estimates respectively. Despite the decline in
domestic duty-free sales as well as its contract manufacturing volume,
BAT’s 9M14 earnings grew 12.6% YoY due to: i) a 4.9% revenue growth
on the back of the cumulative effect of the price hikes in June and
September last year, ii) an absence of non-recurring leaf restructuring
expenses in 2013, and iii) cost savings from improved productivity. A
third interim dividend per share of 78 sen was declared for the quarter
under review.
Outlook. Although it seems as if the industry has turned the corner,
given the decline in illegal cigarette incidences and the absence of a hike
in excise duty, we remain cautious on its longer-term outlook. This is
given the continued decline in legal sales from the stubbornly high level
of illegal cigarette trade, plus the risk of an off-budget excise duty hike.
Forecasts and risks. In view of the better-than-expected 9M14
earnings, we lift our earnings estimates for FY14 and FY15 by 7.3% and
3.9% respectively. We also take this opportunity to introduce our FY16
projections. Key risks to our forecasts include a stronger sales volume
and lower-than-expected raw material costs.
Investment case. We nudge our DCF-based TP higher to MYR57.80
(from MYR56.00) (WACC: 7.2%, TG: 1.5%) following the revision to our
forecasts. With its unattractive valuations relative to its earnings growth
as well as unappealing dividend yield, we reiterate our SELL
recommendation on the stock. The stock is currently trading at a 21.7x
FY15 P/E (+1SD from its historical 5-year mean).
Forecasts and Valuations
Dec-12
Dec-13
Dec-14F
Dec-15F
Dec-16F
4,365
4,517
4,594
4,507
4,569
Reported net profit (MYRm)
798
823
917
877
957
Recurring net profit (MYRm)
798
823
917
877
957
Recurring net profit growth (%)
10.9
3.2
11.3
(4.3)
9.1
Recurring EPS (MYR)
2.79
2.88
3.21
3.07
3.35
DPS (MYR)
2.72
2.82
3.15
3.01
3.29
Recurring P/E (x)
23.9
23.1
20.8
21.7
19.9
Fong Kah Yan +603 9207 7668
P/B (x)
39.3
37.5
36.2
35.0
33.8
fong.kah.yan@rhbgroup.com
P/CF (x)
26.0
23.3
18.4
20.0
18.6
4.1
4.2
4.7
4.5
4.9
17.2
16.5
14.9
15.6
14.6
174.1
165.8
177.2
164.0
173.0
86.9
88.6
68.6
58.7
50.1
1.6
(5.1)
0.9
Share Performance (%)
Absolute
Relative
YTD
1m
3m
6m
12m
4.1
(5.8)
(2.0)
8.4
6.1
8.4
(2.5)
3.3
11.6
6.4
Shariah compliant
Total turnover (MYRm)
Dividend Yield (%)
EV/EBITDA (x)
Return on average equity (%)
Net debt to equity (%)
Our vs consensus EPS (adjusted) (%)
Source: Company data, RHB
See important disclosures at the end of this report
Powered by EFATM Platform
6
Corporate News Flash, 17 October 2014
KPJ Healthcare (KPJ MK)
Neutral (Maintained)
Consumer Non-cyclical - Healthcare
Market Cap: USD1,147m
Target Price:
Price:
MYR3.67
MYR3.71
Macro
Risks
Taking Steps To Address Growing Demand
Growth
Value
KPJ Healthcare (KPJ MK)
Relative to FTSE Bursa Malaysia KLCI Index (RHS)
98
3.80
93
3.60
88
3.40
83
3.20
78
3.00
73
2.808
7
6
5
4
3
2
1
68
Jun-14
Feb-14
Aug-14
4.00
Apr-14
103
Dec-13
4.20
Oct-13
Vol m
Price Close
0
0
.
2
0
0
We see the MOU that KPJ signed for the development of KPJ .
0
Damansara Specialist 2 as positive and long overdue. The new hospital 0
is slated to cater to the rising demand for private healthcare in the 0
Damansara-Sungai Buloh vicinity. As the building will take 36 months
to complete, we maintain our earnings forecasts at this juncture.
Maintain NEUTRAL with a MYR3.67 TP (1.1% downside, 26x FY15F P/E).


Source: Bloomberg
Avg Turnover (MYR/USD)
Cons. Upside (%)
Upside (%)
52-wk Price low/high (MYR)
Free float (%)
Share outstanding (m)
Shareholders (%)
Johor Corp
EPF
Lembaga Tabung Haji
4.41m/1.37m
-3.8
-1.1
2.98 - 4.05
27
1,014
45.1
12.8
7.9
Share Performance (%)


2

.
2
0
.
2







Details on the MOU. KPJ Healthcare (KPJ) signed a memorandum of
understanding (MOU) on 16 Oct with Pelaburan Hartanah (PHB) and
Nadayu Properties (NPB) for the proposed development and lease of a
purpose-built hospital building, to be known as KPJ Damansara
Specialist 2. The MOU will see NPB developing a 300-bed, 9-storey
hospital building and a 636-bay car park with a certificate of completion
and compliance (CCC) for PHB within 36 months from the agreed
execution date. PHB will then execute a sale-and-purchase agreement
(SPA) with NPB for the purchase of both the land and building.
Subsequently, it will lease the building to KPJ for a 15-year period, with
an option of a renewal for another 15 years. The development will also
include a new exit ramp to the hospital. However, at this point in time,
matters relating to the timeline and costs for the development have yet to
be finalised and disclosed.
Details on the land. The land on which the hospital is to be built is
located in Mukim Batu, close to Sungai Penchala in Kuala Lumpur. The
total area is expected to be approximately 6.176 acres. The hospital will
occupy 2.95 acres of the gross area once it is completed.
Rationale of MOU. The three parties signed the MOU due to increasing
development funding costs. Management believes that established Tier1 hospitals like KPJ Damansara can afford to pay rent immediately,
thereby easing capex that can be channeled towards new hospitals in
smaller towns. KPJ Damansara Specialist has 211 beds currently.
Forecasts. We make no changes to our earnings forecasts at this
juncture as management disclosed that the hospital requires 36 months
to be developed. It also requires an additional 3-6 months to obtain
approvals from relevant authorities before it can be open to public.
Maintain NEUTRAL. We maintain our NEUTRAL call and TP of
MYR3.67 pending further disclosure on the development. Our TP is
pegged to a 26x FY15F P/E, in line with its average 3-year forward P/E.
YTD
1m
3m
6m
12m
Absolute
(4.4)
(2.4)
5.4
14.5
(7.0)
Forecasts and Valuations
Relative
(0.1)
0.9
10.7
17.7
(6.7)
Total turnover (MYRm)
Dec-12
Dec-13
2,096
2,332
2,652
3,041
3,315
Reported net profit (MYRm)
140
103
131
141
149
Recurring net profit (MYRm)
128
98
131
141
149
(11.1)
(23.3)
33.5
7.8
5.7
Recurring EPS (MYR)
0.21
0.12
0.13
0.14
0.15
Alexander Chia +603 9207 7621
DPS (MYR)
0.11
0.06
0.07
0.08
0.08
alexander.chia@rhbgroup.com
Recurring P/E (x)
17.9
30.8
27.8
25.8
24.4
P/B (x)
2.31
3.34
3.17
3.00
2.85
P/CF (x)
11.3
36.2
16.2
17.8
16.2
Dividend Yield (%)
3.1
1.5
2.0
2.1
2.3
EV/EBITDA (x)
7.5
12.7
11.2
10.0
9.0
Return on average equity (%)
14.5
9.6
11.7
11.9
12.0
Net debt to equity (%)
35.4
60.2
31.7
38.6
43.2
19.0
14.9
21.5
Shariah compliant
The Research Team +603 9207 7688
research2@rhbgroup.com
Recurring net profit growth (%)
Our vs consensus EPS (adjusted) (%)
Dec-14F
Dec-15F
Dec-16F
Source: Company data, RHB
See important disclosures at the end of this report
Powered by EFATM Platform
7
RHB Guide to Investment Ratings
Buy: Share price may exceed 10% over the next 12 months
Trading Buy: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain
Neutral: Share price may fall within the range of +/- 10% over the next 12 months
Take Profit: Target price has been attained. Look to accumulate at lower levels
Sell: Share price may fall by more than 10% over the next 12 months
Not Rated: Stock is not within regular research coverage
Disclosure & Disclaimer
All research is based on material compiled from data considered to be reliable at the time of writing, but RHB does not make any representation or
warranty, express or implied, as to its accuracy, completeness or correctness. No part of this report is to be construed as an offer or solicitation of an offer
to transact any securities or financial instruments whether referred to herein or otherwise. This report is general in nature and has been prepared for
information purposes only. It is intended for circulation to the clients of RHB and its related companies. Any recommendation contained in this report does
not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This report is for the
information of addressees only and is not to be taken in substitution for the exercise of judgment by addressees, who should obtain separate legal or
financial advice to independently evaluate the particular investments and strategies.
This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB’s
strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such
information and accordingly investors should make their own informed decisions before relying on the same.
RHB, its affiliates and related companies, their respective directors, associates, connected parties and/or employees may own or have positions in
securities of the company(ies) covered in this research report or any securities related thereto, and may from time to time add to, or dispose off, or may be
materially interested in any such securities. Further, RHB, its affiliates and related companies do and seek to do business with the company(ies) covered
in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies),
may sell them or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory or
underwriting services for or relating to such company(ies), as well as solicit such investment, advisory or other services from any entity mentioned in this
research report.
RHB and its employees and/or agents do not accept any liability, be it directly, indirectly or consequential losses, loss of profits or damages that may arise
from any reliance based on this report or further communication given in relation to this report, including where such losses, loss of profits or damages are
alleged to have arisen due to the contents of such report or communication being perceived as defamatory in nature.
The term “RHB” shall denote where applicable, the relevant entity distributing the report in the particular jurisdiction mentioned specifically herein below
and shall refer to RHB Research Institute Sdn Bhd, its holding company, affiliates, subsidiaries and related companies.
All Rights Reserved. This report is for the use of intended recipients only and may not be reproduced, distributed or published for any purpose without prior
consent of RHB and RHB accepts no liability whatsoever for the actions of third parties in this respect.
Malaysia
This report is published and distributed in Malaysia by RHB Research Institute Sdn Bhd (233327-M), Level 11, Tower One, RHB Centre, Jalan Tun Razak,
50400 Kuala Lumpur, a wholly-owned subsidiary of RHB Investment Bank Berhad (RHBIB), which in turn is a wholly-owned subsidiary of RHB Capital
Berhad.
Singapore
This report is published and distributed in Singapore by DMG & Partners Research Pte Ltd (Reg. No. 200808705N), a wholly-owned subsidiary of DMG &
Partners Securities Pte Ltd, a joint venture between Deutsche Asia Pacific Holdings Pte Ltd (a subsidiary of Deutsche Bank Group) and OSK Investment
Bank Berhad, Malaysia which have since merged into RHB Investment Bank Berhad (the merged entity is referred to as “RHBIB”, which in turn is a whollyowned subsidiary of RHB Capital Berhad). DMG & Partners Securities Pte Ltd is a Member of the Singapore Exchange Securities Trading Limited. DMG &
Partners Securities Pte Ltd may have received compensation from the company covered in this report for its corporate finance or its dealing activities; this
report is therefore classified as a non-independent report.
As of 28 16 October 2014May 2014, DMG & Partners Securities Pte Ltd and its subsidiaries, including DMG & Partners Research Pte Ltd do not have
proprietary positions in the securities covered in this report, except for:
a)
-As of 28 16 October 2014May 2014, none of the analysts who covered the securities in this report has an interest in such securities, except for:
a)
KPJ HealthcarSpecial Distribution by RHB
Where the research report is produced by an RHB entity (excluding DMG & Partners Research Pte Ltd) and distributed in Singapore, it is only distributed
to "Institutional Investors", "Expert Investors" or "Accredited Investors" as defined in the Securities and Futures Act, CAP. 289 of Singapore. If you are not
an "Institutional Investor", "Expert Investor" or "Accredited Investor", this research report is not intended for you and you should disregard this research
report in its entirety. In respect of any matters arising from, or in connection with this research report, you are to contact our Singapore Office, DMG &
Partners Securities Pte Ltd
Hong Kong
This report is published and distributed in Hong Kong by RHB OSK Securities Hong Kong Limited (“RHBSHK”) (formerly known as OSK Securities Hong
8
Kong Limited), a subsidiary of OSK Investment Bank Berhad, Malaysia which have since merged into RHB Investment Bank Berhad (the merged entity is
referred to as “RHBIB”), which in turn is a wholly-owned subsidiary of RHB Capital Berhad.
RHBSHK, RHBIB and/or other affiliates may beneficially own a total of 1% or more of any class of common equity securities of the subject company.
RHBSHK, RHBIB and/or other affiliates may, within the past 12 months, have received compensation and/or within the next 3 months seek to obtain
compensation for investment banking services from the subject company.
Risk Disclosure Statements
The prices of securities fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that
losses will be incurred rather than profit made as a result of buying and selling securities. Past performance is not a guide to future performance. RHBSHK
does not maintain a predetermined schedule for publication of research and will not necessarily update this report
Indonesia
This report is published and distributed in Indonesia by PT RHB OSK Securities Indonesia (formerly known as PT OSK Nusadana Securities Indonesia), a
subsidiary of OSK Investment Bank Berhad, Malaysia, which have since merged into RHB Investment Bank Berhad, which in turn is a wholly-owned
subsidiary of RHB Capital Berhad.
Thailand
This report is published and distributed in Thailand by RHB OSK Securities (Thailand) PCL (formerly known as OSK Securities (Thailand) PCL), a
subsidiary of OSK Investment Bank Berhad, Malaysia, which have since merged into RHB Investment Bank Berhad, which in turn is a wholly-owned
subsidiary of RHB Capital Berhad.
Other Jurisdictions
In any other jurisdictions, this report is intended to be distributed to qualified, accredited and professional investors, in compliance with the law and
regulations of the jurisdictions.
DMG & Partners Research Guide to Investment Ratings
Kuala Lumpur
Hong Kong
Singapore
Malaysia
Tel : +(60) 3 9280 2185
Fax : +(60) 3 9284 8693
19 Des Voeux Road
Central, Hong Kong
Tel : +(852) 2525 1118
Fax : +(852) 2810 0908
Tel : +(65) 6533 1818
Fax : +(65) 6532 6211
Buy: Share price may exceed 10% over the next 12 months
Trading Buy:Malaysia
Share price
may exceed 15% over theRHB
nextOSK
3 months,
however longer-term outlook remains uncertain
Research Office
Securities Hong Kong Ltd. (formerly known
DMG & Partners
Neutral: Share
mayInstitute
fall within
months
as 12
OSK
Securities
Securities Pte. Ltd.
RHB price
Research
Sdn the
Bhdrange of +/- 10% over the next
Take Profit:
Target
price
has
been
attained.
Look
to
accumulate
at
lower
levels
Hong Kong Ltd.)
Level 11, Tower One, RHB Centre
10 Collyer Quay
Sell: Share price may
more than 10% over the next 12 months
Jalanfall
TunbyRazak
12th Floor
#09-08 Ocean Financial Centre
Lumpur
World-Wide House
Singapore 049315
Not Rated: Stock isKuala
not within
regular research coverage
DISCLAIMERS
Phnom
Penh
This research is issuedJakarta
by DMG & Partners Research Pte Ltd and it is forShanghai
general distribution only. It does not have any regard
to the
specific investment
objectives, financial situation and particular needs of any specific recipient of this research report. You should independently evaluate particular
PT RHB OSK and
Securities
Indonesia
(formerlyfinancial
known asadviser
RHB
OSK (China)
Advisory
Ltd. into any
RHBtransaction
OSK Indochina
Securities
Limited
(formerly
investments
consult
an independent
before
makingInvestment
any investments
or Co.
entering
in relation
to any
securities
or
PT OSKmentioned
Nusadana in this report.
(formerly known as OSK (China) Investment
known as OSK Indochina Securities Limited)
investment instruments
Securities Indonesia)
Plaza CIMB Niaga
Advisory Co. Ltd.)
Suite 4005, CITIC Square
No. 1-3, Street 271
Sangkat Toeuk Thla, Khan Sen Sok
Tel : +(6221) 2598 6888
Tel : +(8621) 6288 9611
Fax: +(855) 23 969 171
The information contained
herein has been obtained from sources 1168
we believed
to be reliable but we do not make any representation
or warranty nor
14th Floor
Nanjing West Road
Phnom Penh
accept any responsibility
or liability
as to its accuracy, completeness orShanghai
correctness.
are subject to change
Jl. Jend. Sudirman
Kav.25
20041Opinions and views expressed in this report
Cambodia
without notice.
Jakarta Selatan 12920, Indonesia
China
Tel: +(855) 23 969 161
Fax
: +(6221)
2598or6777
Faxof: +(8621)
6288
9633or sell any securities.
This report does
not
constitute
form part of any offer or solicitation
any offer
to buy
Bangkok
DMG & Partners Research Pte Ltd is a wholly-owned subsidiary of DMG & Partners Securities Pte Ltd, a joint venture between OSK Investment Bank
Berhad, Malaysia which have since merged into RHBRHB
Investment
Bank Berhad (the merged entity is referred to as “RHBIB” which in turn is a whollyOSK Securities (Thailand) PCL (formerly known
owned subsidiary of RHB Capital Berhad) and Deutsche Asiaas
Pacific
Holdings Pte
Ltd (a PCL)
subsidiary of Deutsche Bank Group). DMG & Partners Securities
OSK Securities
(Thailand)
Pte Ltd is a Member of the Singapore Exchange Securities Trading
Limited.
10th Floor,
Sathorn Square Office Tower
98, North Sathorn Road,Silom
Bangkok 10500
DMG & Partners Securities Pte Ltd and their associates, directors,Bangrak,
and/or employees
may have positions in, and may effect transactions in the securities
Thailand
covered in the report, and may also perform or seek to perform broking and
other corporate finance related services for the corporations whose securities
Tel: +(66) 2 862report.
9999
are covered in the report. This report is therefore classified as a non-independent
Fax : +(66) 2 108 0999
As of 16 October 2014, DMG & Partners Securities Pte Ltd and its subsidiaries, including DMG & Partners Research Pte Ltd, do not have proprietary
positions in the subject companies, except for:
a)
As of 16 October 2014, none of the analysts who covered the stock in this report has an interest in the subject companies covered in this report, except
for:
a) KPJ Healthcar
DMG & Partners Research Pte. Ltd. (Reg. No. 200808705N)
9